The American Journal of Medicine
Volume 122, Issue 5, Supplement , Pages S16-S22 , May 2009

Treatment of Patients with Hypertension and Arthritis Pain: New Concepts

  • Michael A. Weber, MD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Michael A. Weber, MD, Downstate College of Medicine, State University of New York, 308 East 38th Street, Suite 201, New York, New York 10022

References 

  1. Mason RP, Kubant R, Jacob RF, Walter MF, Boychuk B, Malinski T. Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: role of antioxidant activity. J Cardiovasc Pharmacol. 2006;48:862–869
  2. Panza JA, Quyyumi AA, Callahan TS, Epstein SE. Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension. J Am Coll Cardiol. 1993;21:1145–1151
  3. Elliott TG, Cockcroft JR, Groop PH, Viberti GC, Ritter JM. Inhibition of nitric oxide synthesis in forearm vasculature of insulin-dependent diabetic patients: blunted vasoconstriction in patients with microalbuminuria. Clin Sci (Lond). 1993;85:687–693
  4. Calver A, Collier J, Vallance P. Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. J Clin Invest. 1992;90:2548–2554
  5. Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation. 1993;88:2510–2516
  6. Williams SB, Cusco JA, Roddy MA, Johnstone MT, Creager MA. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol. 1996;27:567–574
  7. Campia U, Choucair WK, Bryant MB, Waclawiw MA, Cardillo C, Panza JA. Reduced endothelium-dependent and -independent dilation of conductance arteries in African Americans. J Am Coll Cardiol. 2002;40:754–760
  8. Perticone F, Ceravolo R, Pujia A, et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation. 2001;104:191–196
  9. Giles TD. Aspects of nitric oxide in health and disease: a focus on hypertension and cardiovascular disease. J Clin Hypertens (Greenwich). 2006;8(suppl 4):2–16
  10. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115:1634–1642
  11. Wallace JL, Cirino G. The development of gastrointestinal-sparing nonsteroidal anti-inflammatory drugs. Trends Pharmacol Sci. 1994;15:405–406
  12. Muscara MN, McKnight W, Lovren F, Triggle CR, Cirino G, Wallace JL. Antihypertensive properties of a nitric oxide-releasing naproxen derivative in two-kidney, one-clip rats. Am J Physiol Heart Circ Physiol. 2000;279:H528–H535
  13. Wallace JL, Reuter B, Cicala C, McKnight W, Grisham MB, Cirino G. Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology. 1994;107:173–179
  14. Cicala C, Ianaro A, Fiorucci S, et al. NO-naproxen modulates inflammation, nociception and downregulates T cell response in rat Freund's adjuvant arthritis. Br J Pharmacol. 2000;130:1399–1405
  15. Wallace JL, Del Soldato P. The therapeutic potential of NO-NSAIDs. Fundam Clin Pharmacol. 2003;17:11–20
  16. Naproxcinod. Data on file. NiCox, Sophia Antipolis, France, 2006.
  17. Whittle BJ. Neuronal and endothelium-derived mediators in the modulation of the gastric microcirculation: integrity in the balance [Thirteenth Gaddum Memorial Lecture]. Br J Pharmacol. 1993;110:3–17
  18. Wallace JL. Cooperative modulation of gastrointestinal mucosal defence by prostaglandins and nitric oxide. Clin Invest Med. 1996;19:346–351
  19. Rossoni G, Manfredi B, Del Soldato P, Berti F. The nitric oxide-releasing naproxen derivative displays cardioprotection in perfused rabbit heart submitted to ischemia-reperfusion. J Pharmacol Exp Ther. 2004;310:555–562
  20. Rossoni G, Manfredi B, De Gennaro Colonna V, et al. Nitric oxide and prostacyclin pathways: an integrated mechanism that limits myocardial infarction progression in anaesthetized rats. Pharmacol Res. 2006;53:359–366
  21. Davies NM, Roseth AG, Appleyard CB, et al. NO-naproxen vs. naproxen: ulcerogenic, analgesic and anti-inflammatory effects. Aliment Pharmacol Ther. 1997;11:69–79
  22. Silverstein FE, Faich G, Goldstein JL, et al. Celecoxib Long-term Arthritis Safety Study Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study (A randomized controlled trial). JAMA. 2000;284:1247–1255
  23. Fiorucci S, Santucci L, Wallace JL, et al. Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa. Proc Natl Acad Sci U S A. 2003;100:10937–10941
  24. Fiorucci S, de Lima OM, Mencarelli A, et al. Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage. Gastroenterology. 2002;123:1598–1606
  25. Fiorucci S, Di Lorenzo A, Renga B, Farneti S, Morelli A, Cirino G. Nitric oxide (NO)-releasing naproxen (HCT-3012 [(S)-6-methoxy-α-methyl-2-naphthaleneacetic Acid 4-(nitrooxy)butyl ester]) interactions with aspirin in gastric mucosa of arthritic rats reveal a role for aspirin-triggered lipoxin, prostaglandins, and NO in gastric protection. J Pharmacol Exp Ther. 2004;311:1264–1271
  26. Presotto C, Bolla MI, Olivieri R, Schnitzer TJ, Wallace JL. HCT 3012 reduces blood pressure in the spontaneously hypertensive rat model. Arthritis Rheum. 2006;54(suppl):Presentation 231. S147.
  27. Muscara MN, McKnight W, Del Soldato P, Wallace JL. Effect of a nitric oxide-releasing naproxen derivative on hypertension and gastric damage induced by chronic nitric oxide inhibition in the rat. Life Sci. 1998;62:PL235–PL240
  28. Lohmander LS, McKeith D, Svensson O, et al. A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis. Ann Rheum Dis. 2005;64:449–456
  29. Schnitzer TJ, Kivitz AJ, Lipetz RS, Sanders N, Hee A. Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of osteoarthritis of the knee. Arthritis Rheum. 2005;53:827–837

 As of time of publication, rofecoxib has been removed from the market by the manufacturer.

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

PII: S0002-9343(09)00208-3

doi: 10.1016/j.amjmed.2009.03.004

The American Journal of Medicine
Volume 122, Issue 5, Supplement , Pages S16-S22 , May 2009

Article Tools

* Image Usage & Resolution